Medical Management of Brain AVMs Superior to Interventions

Patients were randomly assigned to medical management alone, or with an interventional therapy that included neurosurgery, embolization, or stereotactic radiotherapy. The primary outcome was time to death or symptomatic stroke as confirmed by imaging.

The results revealed that during a mean follow-up of 50.4 months, the primary outcome was lower with medical management alone (3.39 per 100 patient-years) than medical management with interventional therapy (12.32 per 100 patient-years); two patients in the medical management group and four in the interventional therapy group died during follow-up. Adverse events were observed less often in patients allocated to medical management compared with interventional therapy (58.97 versus 78.73 per 100 patient-years). The study was published in the July 2020 issue of The Lancet Neurology.

“The study showed that medical management alone remained superior to interventional therapy for the prevention of death or symptomatic stroke in patients with an unruptured brain AVM, “concluded lead author Professor JayMohr, MD, of CU Irving Medical Center. “The data concerning the disparity in outcomes should affect standard specialist practice and the information presented to patients. The even longer-term risks and differences between the two therapeutic approaches remains uncertain.”

A brain AVM is a tangle of abnormal blood vessels connecting arteries and veins in the brain, directing blood away from normal brain tissue. These abnormal and weak blood vessels dilate over time, and may burst eventually from the high pressure of blood flow from the arteries. Symptoms vary, with up to 50% suffering an intracranial hemorrhage, and 25% having focal or generalized seizures. AVMs are usually congenital, and occur in less than one percent of the general population.

Related Links:
Columbia University
Icahn School of Medicine at Mount Sinai